BR112018010418A8 - complexo de agente quimioterápico em microbolhas para terapia sonodinâmica - Google Patents

complexo de agente quimioterápico em microbolhas para terapia sonodinâmica

Info

Publication number
BR112018010418A8
BR112018010418A8 BR112018010418A BR112018010418A BR112018010418A8 BR 112018010418 A8 BR112018010418 A8 BR 112018010418A8 BR 112018010418 A BR112018010418 A BR 112018010418A BR 112018010418 A BR112018010418 A BR 112018010418A BR 112018010418 A8 BR112018010418 A8 BR 112018010418A8
Authority
BR
Brazil
Prior art keywords
microbubble
chemotherapeutic agent
agent complex
sonodynamic therapy
sonodynamic
Prior art date
Application number
BR112018010418A
Other languages
English (en)
Other versions
BR112018010418A2 (pt
Inventor
Mchale Anthony
Stride Eleanor
Callan John
Original Assignee
Univ Ulster
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ulster filed Critical Univ Ulster
Publication of BR112018010418A2 publication Critical patent/BR112018010418A2/pt
Publication of BR112018010418A8 publication Critical patent/BR112018010418A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A61K41/0033—Sonodynamic cancer therapy with sonochemically active agents or sonosensitizers, having their cytotoxic effects enhanced through application of ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

a invenção refere-se a métodos de terapia sonodinâmica compreendendo a coadministração de um complexo de agente quimioterápico em microbolhas junto com um complexo sonossensibilizador de microbolhas. a invenção se refere ainda a composições farmacêuticas compreendendo estes complexos e seu uso em métodos de terapia sonodinâmica e/ou diagnóstico sonodinâmico. tais métodos encontram uso particular no tratamento de câncer, por exemplo, câncer pancreático.
BR112018010418A 2015-11-23 2016-11-23 complexo de agente quimioterápico em microbolhas para terapia sonodinâmica BR112018010418A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1520649.3A GB201520649D0 (en) 2015-11-23 2015-11-23 Sonodynamic therapy
PCT/GB2016/053682 WO2017089800A1 (en) 2015-11-23 2016-11-23 Microbubble-chemotherapeutic agent complex for sonodynamic therapy

Publications (2)

Publication Number Publication Date
BR112018010418A2 BR112018010418A2 (pt) 2018-11-21
BR112018010418A8 true BR112018010418A8 (pt) 2019-02-26

Family

ID=55133235

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018010418A BR112018010418A8 (pt) 2015-11-23 2016-11-23 complexo de agente quimioterápico em microbolhas para terapia sonodinâmica

Country Status (12)

Country Link
US (2) US11382987B2 (pt)
EP (1) EP3380123A1 (pt)
JP (1) JP7080820B2 (pt)
KR (1) KR20180120671A (pt)
CN (1) CN108601835B (pt)
AU (1) AU2016358441B2 (pt)
BR (1) BR112018010418A8 (pt)
CA (1) CA3006018A1 (pt)
GB (1) GB201520649D0 (pt)
SG (1) SG11201804312RA (pt)
WO (1) WO2017089800A1 (pt)
ZA (1) ZA201804141B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9572591B2 (en) 2013-09-03 2017-02-21 United States Endoscopy Group, Inc. Endoscopic snare device
US10667838B2 (en) * 2017-01-09 2020-06-02 United States Endoscopy Group, Inc. Endoscopic snare device
GB201708663D0 (en) * 2017-05-31 2017-07-12 Univ Ulster Therapy
KR20210036307A (ko) * 2018-03-23 2021-04-02 아데노사이트 엘엘씨 향상된 세포병리학적 세포 수집을 위해 세포 및/또는 조직 단편의 박리를 유도하는 방법
US20210361575A1 (en) * 2018-04-11 2021-11-25 New Mexico Tech University Research Park Corporation Lipid prodrugs for use in drug delivery
CN109223800A (zh) * 2018-10-26 2019-01-18 辽宁大学 3,7-二对甲苯胺基-吩噻嗪-5-鎓碘化物与超声协同在抑制肿瘤细胞增殖中的应用
GB201819853D0 (en) 2018-12-05 2019-01-23 Innovation Ulster Ltd Therapy
CN109529063B (zh) * 2019-01-18 2020-02-18 北京大学 一种用于超声诊断和声动力治疗的微泡制剂及其制备方法
CA3128067A1 (en) 2019-02-13 2020-08-20 Alpheus Medical, Inc. Non-invasive sonodynamic therapy
GB201908352D0 (en) 2019-06-11 2019-07-24 Innovation Ulster Ltd Sonodynamic therapy
GB201909692D0 (en) 2019-07-05 2019-08-21 Innovation Ulster Ltd Sonodynamic therapy
US11883679B2 (en) * 2019-10-11 2024-01-30 North Carolina State University Systems and methods for ultrasound induced thrombolysis with magnetic microbubbles, optional nanodroplets, and a rotational magnetic field
CN113925965A (zh) * 2020-07-14 2022-01-14 上海释康企业管理咨询合伙企业(有限合伙) 用于声动力疗法的靶向声敏剂复合物及其应用
CN113198117B (zh) * 2020-08-18 2023-12-22 于波 二氢卟吩衍生物与超声医疗系统的组合
KR102398743B1 (ko) 2020-09-03 2022-05-16 충남대학교병원 초음파유도 마이크로버블을 포함하는 배뇨장애 치료제 조성물
CN112472819B (zh) * 2020-11-30 2022-04-22 西安交通大学 一种共载阿霉素和吲哚菁绿的多糖基纳米粒子及其制备方法和应用
CN112641943A (zh) * 2020-12-28 2021-04-13 新乡医学院 一种载抗肿瘤药物的超声给药微泡复合物及其制备方法与应用
KR20230117807A (ko) * 2022-02-03 2023-08-10 인천대학교 산학협력단 화학-초음파동역학 치료를 위한 이중 자극 감응성 약물 방출형 세포 외 소포체
CN114984251A (zh) * 2022-05-12 2022-09-02 云南大学附属医院 一种携双功能配体超声靶向微泡的制备方法及其应用
CN115040773B (zh) * 2022-06-22 2023-10-13 西南交通大学 一种治疗慢性感染创面的微针贴片及其制备方法和应用
KR20240013509A (ko) * 2022-07-22 2024-01-30 (주)아이엠지티 초음파 감응형 포피린-리포좀 및 이의 용도
CN116444376B (zh) * 2023-04-19 2024-01-26 德兴市德邦化工有限公司 一种3,5-二氯硝基苯的生产工艺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044354A1 (en) 2001-08-16 2003-03-06 Carpenter Alan P. Gas microsphere liposome composites for ultrasound imaging and ultrasound stimulated drug release
US20090117177A1 (en) 2005-05-23 2009-05-07 Natalia Rapoport Echogenic microbubbles and microemulsions for ultrasound-enhanced nanoparticle-mediated delivery of agents
DE102007041832A1 (de) 2007-09-03 2009-03-05 Siemens Ag Arzneimittel und Verfahren zur Behandlung von Prostatakrebs
ES2740633T3 (es) 2007-10-26 2020-02-06 Univ Virginia Patent Foundation Sistema para el tratamiento y la formación de imágenes utilizando energía ultrasónica y microburbujas
EP2253308A1 (en) 2009-05-22 2010-11-24 Ludwig-Maximilians-Universität München Pharmaceutical composition comprising microbubbles for targeted tumor therapy
GB201106803D0 (en) * 2011-04-21 2011-06-01 Univ Ulster Sonodynamic therapy
US20130072854A1 (en) 2011-09-19 2013-03-21 General Electric Company Microbubble complexes and methods of use
WO2013052776A1 (en) 2011-10-07 2013-04-11 Cedars-Sinai Medical Center Compositions and methods for tumor imaging and targeting by a class of organic heptamethine cyanine dyes that possess dual nuclear and near-infrared properties
US8748446B2 (en) 2012-03-03 2014-06-10 Nanoquantum Sciences, Inc. Halogenated compounds for photodynamic therapy
EP3044590A4 (en) * 2013-09-13 2017-09-20 The University of North Carolina at Chapel Hill Methods and compositions for tumor vasculature imaging and targeted therapy
KR101595795B1 (ko) 2014-03-19 2016-02-22 (주)아이엠지티 약물을 함유한 나노입자가 결합된 이중-목적 paｔ／초음파 조영제 및 이의 제조방법

Also Published As

Publication number Publication date
KR20180120671A (ko) 2018-11-06
CA3006018A1 (en) 2017-06-01
CN108601835B (zh) 2022-06-28
SG11201804312RA (en) 2018-06-28
GB201520649D0 (en) 2016-01-06
US20220347314A1 (en) 2022-11-03
BR112018010418A2 (pt) 2018-11-21
WO2017089800A1 (en) 2017-06-01
JP2019500410A (ja) 2019-01-10
AU2016358441A1 (en) 2018-06-07
US20180344872A1 (en) 2018-12-06
JP7080820B2 (ja) 2022-06-06
ZA201804141B (en) 2019-09-25
AU2016358441B2 (en) 2022-08-25
US11382987B2 (en) 2022-07-12
CN108601835A (zh) 2018-09-28
EP3380123A1 (en) 2018-10-03

Similar Documents

Publication Publication Date Title
BR112018010418A2 (pt) complexo de agente quimioterápico em microbolhas para terapia sonodinâmica
CY1122038T1 (el) Ετεροδιλειτουργικοι αναστολεις των ε-σελεκτινων και των υποδοχεων χημειοκινης cxcr4
CO2018003542A2 (es) Anticuerpo anti-garp
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
MY187540A (en) Compounds active towards bromodomains
PH12015502261A1 (en) Macrocyclic deaza-purinones for the treatment of viral infections
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
BR112018008601A2 (pt) composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
CY1122968T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικο
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
PH12019501199A1 (en) Calcium lactate compositions and methods of use
NI201500118A (es) Imidazopiridazinas sustituidas
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
BR112018002520A2 (pt) Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncer
BR112018002530A2 (pt) combinações e usos e tratamentos destas
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
BR112016026545A8 (pt) eribulina ou um sal farmaceuticamente aceitável do mesmo, seus usos e kit para utilização no tratamento de câncer da mama
NZ745187A (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
BR112013019680A2 (pt) combinações compreendendo macitentana para o tratamento de glioblastoma multiforme
WO2016130581A8 (en) Combination cancer therapy
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
BR112018008076A2 (pt) derivados de lapachona contendo dois centros redox e métodos de uso dos mesmos
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes
CL2015001574A1 (es) Terapia combinada para el cancer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2645 DE 14/09/2021.